Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01683279 · ClinicalTrials.gov registry record · Phase 1
A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia
A Phase 1 study of B-cell Leukemia, sponsored by Seattle Children's Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT01683279: Active Phase 1 study of B-cell Leukemia, sponsored by Seattle Children's Hospital.
NCT01683279 is a Phase 1 study of B-cell Leukemia that is active but no longer recruiting, run by Seattle Children's Hospital. The registered enrollment target is 6 participants, below the 164-participant average among 3 other B-cell Leukemia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01683279, a Phase 1 study of B-cell Leukemia, is active but no longer recruiting, sponsored by Seattle Children's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with relapsed leukemia often develop resistance to chemotherapy. For this reason, we are attempting to use a patient's own T cells, which can be genetically modified to expresses a chimeric antigen receptor(CAR). The CAR enables the T cell to recognize and kill the leukemic cells though the recognition of CD19, a protein expressed on the surface of the majority of pediatric ALL. This is a phase I study designed to determine the maximum tolerated dose of the CAR+ T cells and define the toxicity of the treatment. As a secondary aim, we will be looking at the efficacy of the T cells on eradicating the patient's leukemic cells.
Primary Outcome
The safety of the T cell infusion will be described and the maximum tolerated dose determined.
Conditions Studied
Interventions
- BIOLOGICAL Autologous CD19 CAR+ EGFTt + T cells
Study Locations (1)
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-03-25 |
| Est. Completion | 2030-01-07 |
| Phase | Phase 1 |
What the registry record for NCT01683279 still lists
NCT01683279 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 164-participant average among 3 other B-cell Leukemia trials with a reported enrollment target (96% lower).
The record links to 1 condition, with B-cell Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Autologous CD19 CAR+ EGFTt + T cells is the first listed.
NCT01683279 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT01683279 about?
NCT01683279 is a clinical study titled "A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia". Patients with relapsed leukemia often develop resistance to chemotherapy. For this reason, we are attempting to use a patient's own T cells, which can be genetically modified to expresses a chimeric antigen receptor(CAR). The CAR enables the T cell to recognize and kill the leukemic cells though the...
What is the current status of trial NCT01683279?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2012-03-25. Estimated completion is 2030-01-07.
What conditions does trial NCT01683279 study?
This clinical trial studies the following conditions: B-cell Leukemia.
What interventions are being tested in trial NCT01683279?
The interventions under investigation include: Autologous CD19 CAR+ EGFTt + T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01683279?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01683279 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
RECRUITING · Phase 1
-
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
COMPLETED · Phase 1
-
A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI